The short version.
People sometimes lump AOD-9604 and tirzepatide together as "fat-loss compounds," and that framing hides much more than it reveals. They share almost nothing — different mechanisms, different evidence, different regulatory status, different effect sizes.
Tirzepatide is a dual GLP-1 / GIP receptor agonist, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The SURMOUNT-1 trial showed roughly 20%+ body weight reduction at the highest dose over 72 weeks — the strongest pharmacological weight-loss data in modern medicine.
AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone. Its Phase IIb obesity trial did not separate from placebo. It is not FDA-approved. Patients access it via compounding under a physician's prescription.
| Topic | AOD-9604 | Tirzepatide |
|---|---|---|
| Mechanism | GH fragment 177-191; thought to act via β3 adrenergic / lipolytic pathways | Dual GLP-1 / GIP receptor agonist; appetite + glucose regulation |
| FDA status | Not FDA-approved; available via 503A compounding | FDA-approved (Mounjaro for T2D; Zepbound for obesity) |
| Strongest human evidence | Phase IIb did not beat placebo at 12 weeks | SURMOUNT-1: ~20%+ weight loss at highest dose, 72 weeks |
| Side-effect profile | Generally well-tolerated in trials | GI side effects common; pancreatitis, gallbladder warnings |
| Typical use case | Adjunct in body-recomp protocols | Primary therapy for obesity / T2D |
The mechanisms aren't comparable.
Tirzepatide works centrally and peripherally. By engaging GLP-1 and GIP receptors, it slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. The effect on body weight is dominated by appetite suppression — people simply eat less. The downstream effect is large enough that GLP-1 and GLP-1/GIP agents have rewritten the obesity treatment landscape.
AOD-9604, in contrast, was designed to mimic only the lipolytic C-terminus of GH. The premise was direct stimulation of fat breakdown in adipocytes without the systemic effects of full-length GH. Mechanistically interesting; clinically, the human obesity trial did not show meaningful weight loss vs placebo.
If you're choosing between them as a body-composition tool, tirzepatide and AOD-9604 are not on the same shelf. Tirzepatide is a frontline obesity drug. AOD-9604 is an adjunct compound with limited efficacy data, sometimes used when GLP-1 isn't appropriate or after a GLP-1 course as part of a recomposition phase.
Tirzepatide is a frontline obesity drug. AOD-9604 is a niche adjunct. Treating them as alternatives misreads the evidence.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Am I a candidate for FDA-approved tirzepatide, or are there reasons to avoid GLP-1 therapy?
- If I'm interested in AOD-9604, what's the realistic outcome given the trial data?
- Should I think of AOD-9604 as a primary tool or an adjunct after lifestyle and primary therapy?
- What labs would you want before and during either course?
- How do you think about stacking versus running one at a time?
Sources